Alector to Host R&D Day on December 13, 2019
The event agenda will include a discussion of the Company’s therapeutic approach to neurodegeneration and Alector’s pipeline of novel, genetically validated therapeutics including: Phase 1b data for AL001 for frontotemporal dementia; Phase 1 data for AL002 for Alzheimer’s disease; a Phase 1 study update on AL003 for Alzheimer’s disease; and, an introduction to a new product candidate from the Company’s discovery platform, AL014.
The program will also feature presentations from leading key opinion leaders focused on the human genetics of neurodegeneration, including:
Mario Masellis , MSc (Pharm), M.D., Ph.D., FRCPC
Assistant Professor,Department of Medicine ,Institute of Medical Sciences
Co-director, Cognitive Neurology Research Unit,Sunnybrook Health Sciences Centre
Elizabeth M. Bradshaw , Ph.D.
Adler Assistant Professor of Neurology, theTaub Institute for Research on Alzheimer’s Disease and the Aging Brain and theInstitute for Genomic Medicine ,Colombia University
Carlos Cruchaga , Ph.D.
Professor of Psychiatry and Neurology, Director ofNeuroGenomics and Informatics Washington University inSt. Louis
A live webcast of the event will be available on the “Events & Presentations” page within the Investors section of the Alector website at http://investors.alector.com. A replay will be available on the Alector website for 90 days following the event. For further information, please contact alector@argotpartners.com
About Alector
Contacts
Investors:
ir@alector.com
Media:
1AB
dan@1abmedia.com
Source: Alector, Inc.